Loading…
Shukra Pharmaceuticals (SHUKRAPHAR)₹82.05+0.58%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Shukra Pharmaceuticals reported sales of ₹24.01 Cr, up 379.2% from Jun 2025, and net profit of ₹13.04 Cr, up 1,191.1% year on year. For the year to Mar 2026, sales were ₹57.04 Cr and net profit ₹22.08 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 11.01 | 13.01 | 5.01 | 5.99 | 39.03 | 6.01 | 24.01 |
| Expenses | 7.02 | 6.02 | 4.02 | 6.02 | 12.05 | 6.02 | 4.01 |
| Operating Profit | 4.01 | 7.01 | 1.01 | 0.00 | 27.04 | 1.01 | 19.01 |
| OPM % | 37.0% | 55.0% | 24.0% | −7.0% | 69.0% | 11.0% | 81.0% |
| Other Income | 0.99 | 0.99 | 0.99 | 1.99 | 0.99 | 0.99 | 0.99 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 |
| Profit before tax | 4.01 | 8.02 | 1.01 | 0.00 | 27.05 | 0.00 | 18.03 |
| Tax % | 23.1% | 29.0% | 26.1% | −1,090.0% | 24.0% | 553.1% | 29.0% |
| Net Profit | 3.01 | 5.01 | 1.01 | 2.01 | 20.07 | −2.01 | 13.04 |
| EPS (Rs) | 0.06 | 0.11 | 0.01 | 0.04 | 0.45 | −0.03 | 0.28 |
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| Sales | 33.02 | 57.04 | 75.04 |
| Expenses | 20.07 | 28.07 | 28.10 |
| Operating Profit | 13.01 | 29.02 | 47.06 |
| OPM % | 39.0% | 51.0% | 62.7% |
| Other Income | 3.99 | 4.99 | 4.96 |
| Interest | 1.01 | 1.01 | 0.00 |
| Depreciation | 2.99 | 2.99 | 3.96 |
| Profit before tax | 13.02 | 29.05 | 45.08 |
| Tax % | 28.0% | 23.1% | — |
| Net Profit | 10.03 | 22.08 | 33.11 |
| EPS (Rs) | 0.21 | 0.49 | 0.74 |
| Dividend payout % | 5.0% | 2.0% | — |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 44.01 | 43.99 |
| Reserves | 19.05 | 46.14 |
| Borrowings | 4.01 | 5.01 |
| Other Liabilities | 20.06 | 23.01 |
| Total Liabilities | 87.13 | 117 |
| Fixed Assets | 18.96 | 21.97 |
| CWIP | 2.01 | 12.03 |
| Investments | 0.00 | 0.00 |
| Other Assets | 65.16 | 84.15 |
| Inventories | 9.96 | 13.91 |
| Trade receivables | 8.74 | 22.86 |
| Cash & equivalents | 12.07 | 5.90 |
| Total Assets | 87.13 | 117 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from operating activity | 7.99 | 2.99 |
| Cash from investing activity | −1.01 | −14.04 |
| Cash from financing activity | −5.01 | 5.01 |
| Net cash flow | 1.99 | −6.01 |
| Capex | 2.75 | 15.77 |
| Free cash flow | 4.99 | −12.95 |
| CFO / OP % | 92.0% | 17.0% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor days | 99 | 149 |
| Inventory days | 446 | 319 |
| Days payable | 414 | 232 |
| Cash conversion cycle | 130 | 235 |
| Working capital days | 404 | 353 |
| ROCE % | — | 36.9% |
For the Jun 2026 quarter, Shukra Pharmaceuticals reported sales of ₹24.01 Cr, up 379.2% year on year and net profit of ₹13.04 Cr, up 1,191.1% year on year. The operating margin was 81.0%.
Shukra Pharmaceuticals' sales for the year to Mar 2026 were ₹57.04 Cr; over the last twelve months they were ₹75.04 Cr.
Net profit for the year to Mar 2026 was ₹22.08 Cr, and ₹33.11 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.74.
Shukra Pharmaceuticals reported borrowings of ₹5.01 Cr at Mar 2026, against cash and equivalents of ₹5.90 Cr.
Cash from operations was ₹2.99 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹12.95 Cr.